← Back to Search

SGLT2 Inhibitor

Tropifexor for Non-alcoholic Fatty Liver Disease (ELIVATE Trial)

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, follow-up (up to 62 weeks)
Awards & highlights

Summary

This trial tests two drugs, tropifexor and licogliflozin, both together and separately, to treat adults with a liver condition called NASH. Tropifexor helps reduce liver inflammation and fat buildup, while licogliflozin helps control blood sugar and also reduces liver fat. Tropifexor has shown promise in reducing liver inflammation in preliminary studies, while licogliflozin has demonstrated a significant improvement in liver health in patients with NASH. The goal is to find out if these treatments are safe and effective for people with NASH.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease (NAFLD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, follow-up (up to 62 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, follow-up (up to 62 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Histological Improvement: Number and Percentage of Participants Who Responded at Week 48 Compared With Baseline
Number and Percentage of Participants With Resolution of NASH and no Worsening of Fibrosis
Secondary study objectives
Change From Baseline in Alanine Transaminase (ALT) Over Time
Change From Baseline in Aspartate Aminotransferase (AST) Over Time
Change From Baseline in Gamma-glutamyltransferase (GGT) Over Time
+5 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm C: licogliflozin monotherapyExperimental Treatment1 Intervention
Licogliflozin monotherapy arm: licogliflozin 30 mg tablet (+ placebo matching tropifexor capsule), once daily orally
Group II: Arm B: tropifexor monotherapyExperimental Treatment1 Intervention
Tropifexor monotherapy arm: tropifexor 140 mcg capsule (+ placebo matching licogliflozin tablet), once daily orally
Group III: Arm A: combination therapyExperimental Treatment2 Interventions
Combination therapy arm: tropifexor 140 mcg capsule + licogliflozin 30 mg tablet, once daily orally
Group IV: Arm D: PlaceboPlacebo Group1 Intervention
Placebo arm: placebo matching tropifexor capsule + placebo matching licogliflozin tablet, once daily

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,889 Previous Clinical Trials
4,201,770 Total Patients Enrolled
8 Trials studying Non-alcoholic Fatty Liver Disease
917 Patients Enrolled for Non-alcoholic Fatty Liver Disease
~41 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top